|
Patent landscape, scope, and claims: |
United States Patent 7,250,419: A Detailed Analysis of Scope and Claims
Introduction
United States Patent 7,250,419, titled "Triazolo[4,5-d]pyrimidine compounds," is a significant patent in the pharmaceutical sector, particularly in the development of antiplatelet drugs. This patent, assigned to AstraZeneca UK Limited, involves compounds that act as platelet aggregation inhibitors, which are crucial in the treatment of cardiovascular diseases.
Background
The patent is part of a series of patents related to triazolo[4,5-d]pyrimidine derivatives, which have been extensively researched for their therapeutic potential. The background of this patent includes earlier patents such as U.S. Patent No. 6,525,060, which also deals with similar compounds and their preparation methods[4].
Claims
The patent 7,250,419 includes several claims that define the scope of the invention:
Independent Claims
- The patent claims specific triazolo[4,5-d]pyrimidine compounds, their enantiomers, and pharmaceutically acceptable salts. These compounds are identified by their structural formulas and are characterized by their ability to inhibit platelet aggregation[4].
Dependent Claims
- Dependent claims further specify the methods of preparing these compounds, including various synthetic routes and intermediates. For example, the patent describes the preparation of 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine, a key intermediate in the synthesis of ticagrelor, a well-known antiplatelet drug[4].
Method of Use Claims
- The patent also includes claims related to the methods of using these compounds for treating or preventing thrombotic disorders. This includes dosing regimens and specific indications such as acute coronary syndromes and stroke prevention[4].
Scope of the Patent
The scope of the patent is defined by the breadth of its claims and the specific embodiments described.
Chemical Structure
- The patent covers a specific class of triazolo[4,5-d]pyrimidine compounds with defined structural features. This includes variations in the substituents and the stereochemistry of the compounds[4].
Synthetic Methods
- The patent describes multiple synthetic routes for preparing the claimed compounds, including the use of various solvents and reaction conditions. This provides flexibility in the manufacturing process[4].
Therapeutic Uses
- The scope extends to the therapeutic applications of these compounds, including their use in preventing and treating thrombotic events. This is supported by clinical data and pharmacological studies[4].
Patent Landscape
The patent landscape surrounding U.S. Patent 7,250,419 is complex and involves several related patents and applications.
Related Patents
- Other patents such as U.S. Patent No. 6,525,060 and U.S. Patent No. 6,974,868 also deal with triazolo[4,5-d]pyrimidine derivatives and their applications. These patents form a network of intellectual property that protects various aspects of the compounds and their uses[4].
Litigation and Disputes
- Patents in the pharmaceutical sector are often subject to litigation, especially when generic versions of drugs are developed. For example, disputes over patent infringement, such as those involving Horizon Therapeutics and Par Pharmaceutical, highlight the importance of patent protection in this industry[2].
Examination Process
- The examination process for this patent, as with others, would have involved a thorough review of the claims to ensure they are novel, non-obvious, and enabled. Studies have shown that the examination process tends to narrow the scope of patent claims, ensuring that the granted patents are of higher quality[3].
Impact on the Pharmaceutical Industry
The impact of U.S. Patent 7,250,419 on the pharmaceutical industry is significant.
Drug Development
- The patent has facilitated the development of ticagrelor, a key antiplatelet drug used in the treatment of acute coronary syndromes. This drug has been a major advancement in cardiovascular therapy[4].
Market Competition
- The patent protection afforded by this and related patents has influenced market competition. Generic manufacturers must wait until the patent expires or navigate complex litigation to enter the market with generic versions of the drug[2].
Innovation
- The patent has also driven innovation in the field of antiplatelet therapy. By protecting specific compounds and methods, it has encouraged further research and development of new therapeutic agents[3].
Key Takeaways
- Specific Compounds: The patent covers specific triazolo[4,5-d]pyrimidine compounds and their enantiomers.
- Synthetic Methods: Multiple synthetic routes are described, providing flexibility in manufacturing.
- Therapeutic Uses: The compounds are used in preventing and treating thrombotic disorders.
- Patent Landscape: The patent is part of a complex landscape involving related patents and potential litigation.
- Industry Impact: The patent has facilitated the development of ticagrelor and influenced market competition and innovation.
FAQs
Q1: What is the main subject of U.S. Patent 7,250,419?
- The main subject is triazolo[4,5-d]pyrimidine compounds used as platelet aggregation inhibitors.
Q2: Who is the assignee of this patent?
- The assignee is AstraZeneca UK Limited.
Q3: What is the significance of the synthetic methods described in the patent?
- The synthetic methods provide multiple routes for preparing the compounds, ensuring flexibility and efficiency in manufacturing.
Q4: How does this patent impact the pharmaceutical industry?
- It has facilitated the development of ticagrelor, influenced market competition, and driven innovation in antiplatelet therapy.
Q5: What are some related patents to U.S. Patent 7,250,419?
- Related patents include U.S. Patent No. 6,525,060 and U.S. Patent No. 6,974,868, which also deal with triazolo[4,5-d]pyrimidine derivatives.
Citations
- Tantry et al., Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with cardiovascular diseases.
- McDonnell Boehnen Hulbert & Berghoff LLP, Life Sciences Court Report - September 2018.
- SSRN, Patent Claims and Patent Scope.
- Actavis Group PTC EHF, Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine.
More… ↓
⤷ Subscribe
|
